Victor Manuel Villalobos

A phase 3 randomized, open-label study of pasritamig (JNJ-78278343), a T-cell engager targeting human kallikrein-2, with docetaxel versus docetaxel for metastatic castration-resistant prostate cancer.

Rana R. McKay, Kai‐Jie Yu, Teresa Alonso Gordoa, Johann S. De Bono et autres

TPS5139 Background: Metastatic castration-resistant prostate cancer (mCRPC) remains an incurable disease with high morbidity and a median overall survival of approximately two years. Human kallikrein 2 (KLK2) is highly and specifically expressed in normal and malignant prostate tissue, including late stage mCRPC. …

us, tw, es, gb, de, au, ca, fr, cn (code pays fourni par la source)

Safety and efficacy of pasritamig (PAS) + docetaxel (DOCE) in participants with metastatic castration-resistant prostate cancer (mcrPc): Initial results of a phase 1b study.

M. Patel, Russell Kent Pachynski, Shahneen Sandhu, Aaron Richard Hansen et autres

171 Background: DOCE is a standard of care for pts with mCPRC after androgen receptor pathway inhibitor (ARPI) failure, but more effective regimens are needed. PAS is a first-in-class, bispecific T-cell engaging antibody that binds to the CD3 receptor complex on T …

us, au (code pays fourni par la source)

Pasritamig, a First-in-Class, Bispecific T-Cell Engager Targeting Human Kallikrein 2, in Metastatic Castration-Resistant Prostate Cancer: A Phase I Study

Mark N. Stein, Armelle Vinceneux, Debbie G. J. Robbrecht, Bernard Doger et autres

PURPOSE: We report phase I trial results for pasritamig, a first-in-class, T-cell-engaging bispecific antibody targeting human kallikrein 2 (KLK2) expressed on the surface of prostate cancer (PC) cells. METHODS: Participants had metastatic castration-resistant PC and ≥1 prior therapy. Pasritamig was escalated from …

us, fr, nl, es (code pays fourni par la source)

Phase 1 study results of JNJ-78278343 (pasritamig) in metastatic castration-resistant prostate cancer (mCRPC).

Capucine Baldini, Armelle Vinceneux, Debbie G. J. Robbrecht, Bernard Doger Doger de Spéville et autres

5017 Background: Human kallikrein 2 (encoded by the KLK2 gene and hereafter referred to as KLK2) is a novel target expressed on PC cells with limited normal tissue expression. Pasritamig is a first-in-class T-cell-redirecting bispecific antibody that simultaneously binds KLK2 on PC …

fr, nl, es, us (code pays fourni par la source)

1659TiP A phase I, first-in-human, open-label, multicenter, trial-in-progress of the safety, tolerability, and preliminary efficacy of JNJ-87189401 (PSMA-CD28 bispecific antibody) combined with JNJ-78278343 (KLK2-CD3 bispecific antibody) for advanced prostate cancer

Mark N. Stein, Laura S Graham, Capucine Baldini, Armelle Vinceneux et autres

us, fr (code pays fourni par la source)

Randomized Phase 2 Clinical Trial of Olaratumab in Combination with Gemcitabine and Docetaxel in Advanced Soft Tissue Sarcomas

Steven Attia, Victor Manuel Villalobos, Nadia Hindi, Andrew J. Wagner et autres

Gemcitabine plus docetaxel is an effective treatment regimen for advanced soft tissue sarcomas (STSs). However, the prognosis for patients remains poor, and thus there is an urgent medical need for novel and effective therapies to improve long-term outcomes. The aim of the …

us, es, gb (code pays fourni par la source)

Supplementary Figure S2 from First-in-Human Phase I Study of ABBV-085, an Antibody–Drug Conjugate Targeting LRRC15, in Sarcomas and Other Advanced Solid Tumors

George D. Demetri, Jason J. Luke, Antoine Hollebecque, John D. Powderly et autres

Supplementary Figure S2 shows LRRC15 RNA data from NanoString and clinical response in nonresponder (n=19) and responder (n=5) patients with sarcoma

Supplementary Table S3 from First-in-Human Phase I Study of ABBV-085, an Antibody–Drug Conjugate Targeting LRRC15, in Sarcomas and Other Advanced Solid Tumors

George D. Demetri, Jason J. Luke, Antoine Hollebecque, John D. Powderly et autres

Supplementary Table S3 shows patient demographics and baseline characteristics

Supplementary Table S1 from First-in-Human Phase I Study of ABBV-085, an Antibody–Drug Conjugate Targeting LRRC15, in Sarcomas and Other Advanced Solid Tumors

George D. Demetri, Jason J. Luke, Antoine Hollebecque, John D. Powderly et autres

Supplementary Table S1 shows inclusion and exclusion criteria for each treatment arm that enrolled patients

Supplementary Table S2 from First-in-Human Phase I Study of ABBV-085, an Antibody–Drug Conjugate Targeting LRRC15, in Sarcomas and Other Advanced Solid Tumors

George D. Demetri, Jason J. Luke, Antoine Hollebecque, John D. Powderly et autres

Supplementary Table S2 shows LRRC15 IHC expression in tumor and stroma of patients with sarcoma treated ABBV-085 monotherapy at 3.6 or 4.2 mg/kg

Supplementary Figure S1 from First-in-Human Phase I Study of ABBV-085, an Antibody–Drug Conjugate Targeting LRRC15, in Sarcomas and Other Advanced Solid Tumors

George D. Demetri, Jason J. Luke, Antoine Hollebecque, John D. Powderly et autres

Supplementary Figure S1 shows the study design.

Supplementary Figure S3 from First-in-Human Phase I Study of ABBV-085, an Antibody–Drug Conjugate Targeting LRRC15, in Sarcomas and Other Advanced Solid Tumors

George D. Demetri, Jason J. Luke, Antoine Hollebecque, John D. Powderly et autres

Supplementary Figure S3 shows T-cell infiltration in patients with breast cancer